Prenatal initiation of therapy with mTOR inhibitors for giant cardiac rhabdomyoma

Ultraschall Med 2024; 45(06): 555-556
DOI: 10.1055/a-2408-1068

Title Page

Pränatale Initiierung einer Therapie mit mTOR Inhibitoren bei riesigem kardialem Rhabdomyom

Patrick Schenk

¹Department of Pediatric Cardiology, Pulmonology and Pediatric Intensive Care Medicine, University of Tübingen, Tübingen, Germany

,

Vanya Icheva

¹Department of Pediatric Cardiology, Pulmonology and Pediatric Intensive Care Medicine, University of Tübingen, Tübingen, Germany

,

Michael Hofbeck

¹Department of Pediatric Cardiology, Pulmonology and Pediatric Intensive Care Medicine, University of Tübingen, Tübingen, Germany

,

Markus Hoopmann

²Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany

Literatur
1 Saffari A, Brosse I, Wiemer-Kruel A. et al. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age – a multicenter retrospective study. Orphanet J Rare Dis 2019; 14: 96
2 Hurtado-Sierra D, Ramos Garzon JX, Rojas LZ. et al. Case report: Accelerated regression of giant cardiac rhabdomyomas in neonates with low dose everolimus. Front Pediatr 2023; 11: 1109646
3 Shibata Y, Maruyama H, Hayashi T. et al. Effect and Complications of Everolimus Use for Giant Cardiac Rhabdomyomas with Neonatal Tuberous Sclerosis. AJP Rep 2019; 9: e213-e217
4 Park H, Chang CS, Choi SJ. et al. Sirolimus therapy for fetal cardiac rhabdomyoma in a pregnant woman with tuberous sclerosis. Obstet Gynecol Sci 2019; 62: 280-284